tiprankstipranks
ImmunoCellular Therapeutics (IMUC)
OTHER OTC:IMUC
US Market

ImmunoCellular Therapeutics (IMUC) Income Statement

Compare
180 Followers

ImmunoCellular Therapeutics Income Statement

Last quarter (Q3 2023), ImmunoCellular Therapeutics's total revenue was $0.00, a decrease of ― from the same quarter last year. In Q3, ImmunoCellular Therapeutics's net income was $0.00. See ImmunoCellular Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 23Dec 22Dec 21Dec 20
Total Revenue
$ 0.00$ 0.00$ 0.00$ 0.00
Gross Profit
$ 0.00$ 0.00$ 0.00$ 0.00
Operating Expenses
$ 1.82M$ 2.89M$ 2.61M$ 1.45M
Depreciation and Amortization
$ 167.90K$ 228.49K$ 2.61M$ 1.94M
EBITDA
$ -1.06M$ -2.44M$ -1.00$ 0.00
Operating Income
$ -1.82M$ -2.89M$ -2.61M$ -1.45M
Other Income/Expenses
$ 203.58K$ 238.41K$ -65.71K$ 0.00
Pretax Income
$ -1.61M$ -2.65M$ -2.68M$ -1.45M
Net Income
$ -1.61M$ -2.65M$ -2.68M$ -1.45M
Per Share Metrics
$ ―$ ―$ ―$ ―
Basic EPS
$ -0.01$ -0.02$ -0.06$ -0.03
Diluted EPS
$ -0.01$ -0.02$ -0.06$ -0.03
Weighted Average Shares Outstanding
113.27M 113.27M 45.43M 45.08M
Weighted Average Shares Outstanding (Diluted)
113.27M 113.27M 45.43M 45.08M
Currency in USD

ImmunoCellular Therapeutics Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis